![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Monosomy - 25 Studies Found
Completed |
: Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 :
: 2008-09-26 : Drug: lenalidomide Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increa |
Recruiting |
: Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype : Acute Myeloid Leukemia : 2012-02-13 : Drug: sorafenib, vorinostat and bortezomib Escalating dose cohorts of sorafenib, vorinostat and bortezom |
Active, not recruiting |
: Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia : Leukemia : 2007-11-02 :
|
Recruiting |
: Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma : Uveal Melanoma : 2013-09-17 : Biological: Autologous Dendritic Cells loaded with autologous Tumor RNA |
Completed |
: Prenatal Screening for Down Syndrome With DNAFirst :
: 2008-07-17 : Drug: lenalidomide p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT |
Terminated |
: LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) : AML : 2010-07-29 : Drug: Lenalidomide Initial dose of oral lenalidomide is 10 |
Recruiting |
: SNP-based Microdeletion and Aneuploidy RegisTry (SMART) :
: 2015-03-02 |
Completed |
: A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies :
|
Terminated |
: Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes :
: 2009-06-17 :
|